Tay-Sachs disease
MONDO:0010100GM2 gangliosidosis, variant B or Tay-Sachs disease is marked by accumulation of G2 gangliosides due to hexosaminidase A deficiency.
Also known as: GM2 gangliosidosis, B, B1 variant, GM2-gangliosidosis, several forms, Hex A pseudodeficiency, Tay Sachs Disease, Tay-Sachs disease, disease, Tay-Sachs, hexosaminidase A deficiency, B variant GM2 gangliosidosis
20 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Promising new pill for rare childhood brain diseases enters final testing
Disease control OngoingThis study tests an oral drug called nizubaglustat in children and teens with rare genetic disorders (GM1, GM2 gangliosidosis) that damage the brain and nerves. The goal is to see if the drug can slow disease progression and improve movement and coordination. About 75 participant…
Phase: PHASE3 • Sponsor: Azafaros B.V. • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Gene therapy for rare brain diseases: 5-Year safety check begins
Disease control OngoingThis study follows 7 people who previously received a gene therapy called AXO-AAV-GM2 for Tay-Sachs or Sandhoff disease — rare, fatal genetic disorders that destroy nerve cells. Researchers will track them for up to 5 years to see if the treatment remains safe and whether it help…
Sponsor: Terence Flotte • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC